OR WAIT null SECS
The company invested in the MicroSeq Rapid Microbial Identification System from Applied Biosystems at its Illinois facility.
On July 12, 2016, SGS announced that it has invested in a genotypic DNA sequencing MicroSeq Rapid Microbial Identification System from Applied Biosystems at its Chicago, IL facility, located in the suburb of Lincolnshire. The molecular identification system is undergoing validation and is expected to be fully implemented in Q3, thus enabling the site to provide accurate, high-speed microbiological testing for the identification of microorganisms.
The installation and validation of the new genotypic DNA sequencing MicroSeq ID system will minimize transit delays by consolidating testing requirements through a single laboratory, rapidly obtaining identification of bacterial and fungal isolates, and facilitating a rapid response to the investigation of contamination. The investment at SGS’s Chicago site follows recent microbiological testing expansions at the company’s Villeneuve La Garenne, France facility, which provides services to address the growing biopharmaceutical pipeline with capabilities for mycoplasma tests and amino acid analysis, and in Shanghai, China, where a highly active compound laboratory, designed to test products such as antibodies and hormones, is located.